Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

look forward to completing the follow-up of this initial study and to working with Sangamo as it expands these studies to include the full range of HIV-infected populations."

About SB-728-T

SB-728-T is an autologous CD4+ T-cell product modified with Sangamo's ZFN technology to specifically and permanently modify the cell's own DNA sequence encoding CCR5. CCR5 is the major co-receptor used by HIV to infect cells. A naturally occurring mutation of the CCR5 gene, CCR5-delta32, has been shown to provide protection against HIV infection. Sangamo scientists have demonstrated that CCR5-specific ZFNs can be used to disrupt the CCR5 gene and make human CD4+ T-cells resistant to HIV infection.  Sangamo's SB-728-902 Phase 1 study is designed to evaluate single escalating doses of SB-728-T in subjects that have sub-optimal CD4+ T-cell counts despite long-term HAART and no detectable viral load.  This group represents approximately thirty percent of all HIV-infected patients in the US.  The trial has recently been expanded to add an additional cohort of subjects that are failing HAART and have active viral infections.  In addition, Sangamo has an ongoing Phase 1 / 2 clinical trial, SB-728-1002, in HIV-infected subjects that are viremic but not currently on HAART.  

"While preliminary, these data are very encouraging and an early validation of the feasibility of our novel gene modification approach for the treatment of HIV/AIDS," said Dale Ando, M.D, Sangamo's vice president of therapeutic development and chief medical officer. "The SB-728-902 trial was designed to provide answers to several important questions.  We have confirmed that we have a scalable manufacturing process and that from a single apheresis we can manufacture doses of SB-728-T of 10 to 30 billion cells. We have also learned that a single infusion of these cells is well-tolerated and that the cells engraft, multiply and persist in the body.  The modi
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... LONDON , July 30, 2015 ... devices market ? Which areas are going to grow ... report shows you potential revenues to 2025, assessing data, ... report provides 176 tables, charts, and graphs. ... the future market prospects. Our new study lets you ...
Breaking Medicine Technology:Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... BEIJING, Dec. 31, 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. ... the "Company"), a fast-growing, profitable developer, manufacturer and seller ... China ("PRC"), announced today that the Company will effect ... order to meet minimum share price requirements in connection ...
... WOONSOCKET, R.I., Dec. 31, 2010 CVS Caremark (NYSE: ... into an agreement to acquire the Medicare Part D ... for approximately $1.25 billion.  Universal American is a leading ... New York. The acquisition will more than double the ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a ... treat aging diseases. , BioViva announces it has begun a fundraiser through Maximum ... Disease (AD) and find a cure. MaxLife will grant 100% of the money raised ...
(Date:7/31/2015)... ME (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, ... Glancing out of the window, he recalled that his equipment was set up to depict ... tower, he jumped out of bed. , The photo speaks for itself. Chatfield is also ...
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... Awarded ... Hair Restoration is proud to announce that they are the latest recipients of the ... cements their status as one of the worldwide leaders in the science of hair ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) Medication ... to help long-term and post-acute care providers understand the benefits of using ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce that it ... a mobile application format available on iPhones, iPads, and Android smartphones and tablets. ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3
... 6 May 2010 -- Researchers from Cold Spring Harbor Laboratory ... analyzing the genome of single tumor cells. The breakthrough allows ... tumors develop and has the potential to help doctors identify ... from the prostate or a non-invasive lesion in the breast. ...
... May 2010 -- A new study of metastatic breast ... patients have in their blood directly correlates with the ... Cancer Conference in Brussels, Belgium, the results have the ... these patients. Circulating tumor cells --cancer cells found ...
... After menopause, 6 to 10 million women take hormone ... progestin, to replace hormones lost from inactive ovaries. Progestin ... potentially negative effects of estrogen therapy on the uterus. ... evidence has been found that estrogen and progestin in ...
... ... , ... (PRWEB) May 6, 2010 -- CosmoCom the global leader in Contact Center Consolidation ... prestigious 2010 Long Island Software Award (LISA). Presented by the Long Island Software and ...
... ... steady employment in a highly competitive market. In order to gain a competitive edge against ... appearance. Non-surgical med spa treatments can offer many benefits during a job hunt. , ... (PRWEB) May 6, 2010 -- With ...
... ... achieving top performance from GPUs in diverse applications using Monte Carlo simulations can now ... Group (NAG). , ... (Vocus) May 6, 2010 -- Developers and researchers who are interested in achieving top ...
Cached Medicine News:Health News:Genome breakthrough allows scientists to identify and profile tumor cells from very small samples 2Health News:Survival in metastatic breast cancer directly linked to circulating tumor cells 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 2Health News:Med Spa Treatments Become More Popular as Unemployment Rates Climb 3Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 2Health News:More GPU Routines for Technical Research Now Available from Numerical Algorithms Group 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: